L+C maxillary anesthesia — Competitive Intelligence Brief

L+C maxillary anesthesia (L+C maxillary anesthesia) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic combination. Area: Anesthesia / Dentistry.

phase 3 Local anesthetic combination Anesthesia / Dentistry Small molecule

Target snapshot

L+C maxillary anesthesia (L+C maxillary anesthesia) — University of Belgrade. L+C maxillary anesthesia is a local anesthetic formulation designed to provide regional anesthesia in the maxillary region of the oral cavity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
L+C maxillary anesthesia TARGET	L+C maxillary anesthesia	University of Belgrade	phase 3	Local anesthetic combination
Remifentanil+Lidocaine	Remifentanil+Lidocaine	The First Affiliated Hospital of Zhengzhou University	marketed	Opioid analgesic + Local anesthetic combination	Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)
Lidocaine-chlorprocaine combination	Lidocaine-chlorprocaine combination	Hadassah Medical Organization	marketed	Local anesthetic combination	Voltage-gated sodium channels
Hydrocortisone acetate and lidocaine hydrochloride	Hydrocortisone acetate and lidocaine hydrochloride	Citius Pharmaceuticals, Inc.	marketed	Topical corticosteroid and local anesthetic combination	Glucocorticoid receptor (hydrocortisone); voltage-gated sodium channels (lidocaine)
Lidocaine/Magnesium	Lidocaine/Magnesium	University of Wisconsin, Madison	marketed	Local anesthetic combination	Voltage-gated sodium channels; NMDA receptor
ketorolac + bupivacaine	ketorolac + bupivacaine	The Hospital for Sick Children	marketed	NSAID + local anesthetic combination	COX-1/COX-2 (ketorolac); voltage-gated sodium channels (bupivacaine)
ropivacaine mixed with dexmedetomidine	ropivacaine mixed with dexmedetomidine	The First Hospital of Qinhuangdao	marketed	Local anesthetic combination with alpha-2 adrenergic agonist	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (dexmedetomidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic combination class)

1. University of Belgrade · 2 drugs in this class
2. Cedars-Sinai Medical Center · 1 drug in this class
3. Cutia Therapeutics（Wuxi）Co.,Ltd · 1 drug in this class
4. East Carolina University · 1 drug in this class
5. Galderma R&D · 1 drug in this class
6. Hadassah Medical Organization · 1 drug in this class
7. University of Alabama at Birmingham · 1 drug in this class
8. University of New Mexico · 1 drug in this class
9. Ain Shams University · 1 drug in this class
10. University of Wisconsin, Madison · 1 drug in this class